A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
25 patients with synDLBCL treated at our institution between 2012 and 2021.
I · Intervention 중재 / 시술
less-intensive CNS-directed therapies, including R-CHOP with intrathecal chemotherapy or high-dose methotrexate
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our findings highlight the need for CNS-penetrant, intensified frontline strategies and support the investigation of Bruton's tyrosine kinase inhibitor-containing regimens in this population. Multicenter collaborative studies with standardized diagnostic and treatment approaches are essential to improve outcomes in synDLBCL.
Synchronous central nervous system (CNS) and systemic diffuse large B-cell lymphoma (synDLBCL) is a rare, aggressive entity with poor prognosis and limited data guiding optimal management.
APA
Ohashi KE, Fukuhara S, et al. (2026). A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis.. International journal of hematology, 123(2), 215-224. https://doi.org/10.1007/s12185-025-04089-8
MLA
Ohashi KE, et al.. "A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis.." International journal of hematology, vol. 123, no. 2, 2026, pp. 215-224.
PMID
41171506 ↗
Abstract 한글 요약
Synchronous central nervous system (CNS) and systemic diffuse large B-cell lymphoma (synDLBCL) is a rare, aggressive entity with poor prognosis and limited data guiding optimal management. We retrospectively analyzed 25 patients with synDLBCL treated at our institution between 2012 and 2021. Among the 20 patients undergoing curative-intent treatment, most received less-intensive CNS-directed therapies, including R-CHOP with intrathecal chemotherapy or high-dose methotrexate. The 3-year progression-free survival rate was 33%, with CNS progression as the predominant site of treatment failure. Genetic profiling in 12 patients revealed a high prevalence (83%) of the MCD subtype, characterized by frequent MYD88 and CD79B mutations, irrespective of immunohistochemical cell-of-origin classification. These findings align with the genetic landscape of primary CNS lymphoma, underscoring the limitations of less-intensive CNS-directed therapies in achieving durable CNS control in synDLBCL. Our findings highlight the need for CNS-penetrant, intensified frontline strategies and support the investigation of Bruton's tyrosine kinase inhibitor-containing regimens in this population. Multicenter collaborative studies with standardized diagnostic and treatment approaches are essential to improve outcomes in synDLBCL.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Lymphoma
- Large B-Cell
- Diffuse
- Retrospective Studies
- Central Nervous System Neoplasms
- Male
- Middle Aged
- Female
- Aged
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Vincristine
- Rituximab
- Cyclophosphamide
- Mutation
- 80 and over
- CD79 Antigens
- Myeloid Differentiation Factor 88
- Doxorubicin
- Prednisone
- Neoplasms
- Multiple Primary
- Methotrexate
… 외 6개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.